Iovance Biotherapeutics, Inc. (IOVA) News
Filter IOVA News Items
IOVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IOVA News Highlights
- For IOVA, its 30 day story count is now at 14.
- Over the past 21 days, the trend for IOVA's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- LUNG, DRUG and TIL are the most mentioned tickers in articles about IOVA.
Latest IOVA News From Around the Web
Below are the latest news stories about IOVANCE BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate IOVA as an investment opportunity.
Why Iovance Biotherapeutics Stock Popped TodayIovance rebounded nicely after yesterday's drop, which came after the FDA put a clinical hold on its cancer-therapy trial. |
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
3 Charts For Investors to Watch Thursday: GC Education, Iovance, EthereumThese two stocks and one cryptocurrency are worth watching today. We discuss why and identify important chart levels to watch. |
Gold nears $2100, biotech stocks on the move: Trending tickersGold (GC=F) prices are inching closer to $2,100 per ounce. It's an area that has been a bit of a resistance level for the precious metal. In the world of biotech, Cytokinetics (CYTK) shares soared more than 80% after a trial for its hear drug showed promising results. Meanwhile, Iovance Biotherapeutics (IOVA) shares fell 18% after the Food and Drug Administration paused clinical trials of a lung cancer treatment following the death of a patient. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient DeathWednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. During the clinical hold, Iovance will pause enrollment and the LN-145 TIL treatment regimen for new patients in IO |
Iovance Plummets as FDA Halts Cancer Drug Trial After Death(Bloomberg) -- Iovance Biotherapeutics Inc. fell the most in more than a year after US regulators paused a study of its lung cancer drug following a patient death. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerApple Resumes Sale of Watches After Appeals Court Lifts US BanBridgewater CEO’s Past Office Romance Led to Favoritism ClaimsXiaomi Unveils Its First EV, With Ambition to Be Ch |
Iovance plunges as FDA halts lung-cancer-drug trial after patient deathThe Food and Drug Administration placed a clinical hold on trials of Iovance's treatment for non-small-cell lung cancer. |
Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient DeathThe FDA places a clinical hold on Iovance’s trial of a lung cancer therapy after the company reports a death potentially related to the treatment. |
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung CancerSAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently |
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on December 21, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 44,175 shares of Iovance’s common stock to four new non-executive employees. The awards |